AC
IKT icon

Armistice Capital’s Inhibikase Therapeutics IKT Stock Holding History

Armistice Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-626,500
Closed -$814K – 270
2024
Q3 		$814K Buy
626,500
+36,925
+6% +$49.4K 0.01% 177
2024
Q2 		$713K Buy
+589,575
New +$1.02M 0.01% 168
2023
Q4 		– Sell
-186,046
Closed -$259K – 330
2023
Q3 		$259K Sell
186,046
-310,501
-63% -$696K ﹤0.01% 189
2023
Q2 		$1.79M Buy
496,547
+3,054
+0.6% +$11.4K 0.03% 150
2023
Q1 		$1.95M Buy
+493,493
New +$2.06M 0.03% 127

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital's IKT Position: Q4 2024 in Review

Armistice Capital sold out of Inhibikase Therapeutics (IKT) in Q4 2024, closing a stake of 626,500 shares — an estimated $814K sold.

Armistice Capital first reported a position in IKT in Q1 2023 and held it in 5 quarters. The position peaked at $1.95M in Q1 2023. 31 funds tracked by Wall St. Rank hold IKT as of Q4 2024.

  • Armistice Capital reported no remaining Inhibikase Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 626,500 Inhibikase Therapeutics shares in Q4 2024, an estimated $814K.
  • Armistice Capital first reported a position in Inhibikase Therapeutics in Q1 2023 and held it in 5 quarters.
  • Armistice Capital's Inhibikase Therapeutics position peaked at $1.95M in Q1 2023.
  • 31 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.